Privia Health (PRVA) Price to Sales (2021 - 2026)

Privia Health has reported Price to Sales for 6 years, with the latest figure at 5.14 in Q2 2026.

• On a quarterly basis, Price to Sales fell 5.13% year-over-year to 5.14 in Q2 2026; TTM through Jun 2026 was 1.38, a 7.2% decrease from a year earlier, with the FY2025 full-year figure at 1.38, up 1.92% from the prior year.
• Price to Sales was 5.14 for Q2 2026 at Privia Health, up from 4.28 in the prior quarter.
• The five-year high for Price to Sales was 11.3 in Q3 2022, with the low at 4.28 in Q1 2026.
• Average Price to Sales over 5 years is 6.52, with a median of 5.64 recorded in 2024.
• The largest YoY upside for Price to Sales was 13.59% in 2022 against a maximum downside of 54.24% in 2022.
• Over 5 years, Price to Sales stood at 7.15 in 2022, then dropped by 13.59% to 6.18 in 2023, then retreated by 17.37% to 5.1 in 2024, then climbed by 6.12% to 5.42 in 2025, then dropped by 5.15% to 5.14 in 2026.
• The last three Price to Sales figures came in at 5.14 (Q2 2026), 4.28 (Q1 2026), and 5.42 (Q4 2025), per Business Quant data.